DailyIQ
|
Sector:HealthcareAll sectors
Last updated 24 minutes ago

RVMD·RVMD

$.
-. (-.%)
After Hours
High
$99.01
Open
$97.84
Market Cap
18.62B
52W High
$124.49
Low
$95.97
P. Close
$147.47
P/E
-
52W Low
$29.17
Fwd P/E
-
Mean Target
-
Technical Score (1D)
55
BUY
News Sentiment
44
BEARISH
Erasca's management recently highlighted ERAS-0015's potency advantage over Revolution Medicines' RMC-6236 during a Guggenheim fireside chat. This advantage, coupled with early clinical responses and improved pharmacokinetics, could influence investor perception of RVMD's competitive positioning in the pan-RAS space. The company is advancing dosing and expects data in the first half of the year, which will be a key catalyst. RVMD presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, which likely covered the company's future prospects and pipeline. Investors should assess the impact of this presentation on RVMD's valuation and growth trajectory. The market will be watching for further details on RVMD's pipeline and any strategic shifts.
Earnings Summary
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers, operating within the Healthcare sector, specifically in Biotechnology. The company's focus is on developing novel therapies for cancer treatment. The provided data only includes one quarter of earnings information. The company's EPS was -$1.12 in Q4 2024, with revenue at $0.0. The company missed estimates. Not enough information is available to analyze historical trends. Recent news indicates that the CEO will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026. Investors should watch for updates on clinical trials or partnerships. Key will be any developments related to the company's pipeline and future prospects.

EPS

EstBeatMiss
$-1.14$-1.09$-1.04$-0.99$-0.94Q4'24
QtrEstActual+/−
Q4'24$-0.96$-1.12-16.1%

Revenue

EstBeatMiss
$-0.15$-0.075$0$0.075$0.15Q4'24
QtrEstActual+/−
Q4'24 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RVMD Stock Snapshot

RVMD is currently trading at $149.82, giving RVMD a market cap of 18.62B. Today's range spans $95.97–$99.01, with shares opening at $97.84 and moving up $2.35 (1.6%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 44/100.

Over the past year RVMD has traded between $29.17 and $124.49 - the current price is +413.6% off the 52-week low and +20.3% from the high.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, RVMD (55/100, HOLD, price $149.82, near 52-week highs) is waiting for that resolution. Sentiment: neutral at 44/100. With 18.62B in market cap, the 52-week range of $29.17–$124.49 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

In neutral phases, large-cap Healthcare names like RVMD are often where sector rotation debates play out quietly — at 18.62B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (44/100) at $149.82 (near 52-week highs) describe a stock that is being considered rather than avoided.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…